Conor Wild
Papers
2
Total Citations
12
H-Index
2
About
Conor Wild is a medicinal chemist and structural biologist whose research focuses on transforming fragment-based drug discovery (FBDD) from a screening-centric approach into a fully integrated hit-to-lead pipeline. His major contribution is the development of **Binding-Site Purification of Actives (B-SPA)**, a groundbreaking methodology that combines multi-step array synthesis with high-throughput crystallography. This innovation directly addresses the field’s long-standing bottleneck: efficiently progressing weak fragment hits into potent lead compounds without the need for multiple, time-consuming design cycles. By enabling the rapid, parallel synthesis and structural validation of hundreds of fragment derivatives directly in the protein binding site, B-SPA dramatically accelerates the hit progression process. His most-cited work (2025, 9 citations) and its companion paper (2024, 3 citations) have already garnered attention for offering a practical, scalable solution to a problem that has limited FBDD’s full potential for decades. Wild’s work is notable for bridging the gap between synthetic chemistry and structural biology, providing a powerful tool for both academic labs and pharmaceutical R&D. His approach promises to unlock the latent value of fragment screening, making it a more reliable engine for discovering novel therapeutics.
Research Focus
Key Achievements
Top Papers
- 1
- 2